School of Medicine
Behavioral Medicine and Psychiatry
Background and Objectives—Rising concerns regarding diversion and misuse of monobuprenorphine for treatment of pregnant women with opioid use disorders have sparked interest in the use of buprenorphine +naloxone to reduce misuse and diversion rates. Examined the relationship of prenatal buprenorphine +naloxone exposure to neonatal outcomes. Methods—This is a retrospective chart review of 26 mother infant dyads in comprehensive medication-assisted treatment with buprenorphine +naloxone during pregnancy. Results—All neonatal birth outcome parameters were within normal ranges, albeit on the lower side of normal for gestational age and birth weight. Only 19% of neonates required morphine pharmacology for NAS. Conclusions—Use of buprenorphine +naloxone shows relative safety in pregnancy. Scientific Significance—These findings can help better guide prescribing practices for pregnant patients at risk for misuse or diversion of buprenorphine.
Digital Commons Citation
Nguyen, Linda; Lander, Laura R.; O'Grady, Kevin E.; Marshalek, Patrick J.; Schmidt, Adrienne; Kelly, Audra K.; and Jones, Hendrée E., "Treating women with opioid use disorder during pregnancy in Appalachia: Initial neonatal outcomes following buprenorphine + naloxone exposure" (2018). Clinical and Translational Science Institute. 834.
Nguyen L, Lander LR, O’Grady KE, et al. Treating women with opioid use disorder during pregnancy in Appalachia: Initial neonatal outcomes following buprenorphine + naloxone exposure. The American Journal on Addictions. 2018;27(2):92-96. doi:10.1111/ajad.12687